TCGA-G2-AA3B-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 65.96583443
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.370
- BILE_ACID_METABOLISM+0.330
- INTERFERON_ALPHA_RESPONSE+0.270
- KRAS_SIGNALING_DN+0.200
- PANCREAS_BETA_CELLS+0.170
- E2F_TARGETS+0.160
- OXIDATIVE_PHOSPHORYLATION+0.150
- XENOBIOTIC_METABOLISM+0.140
- ALLOGRAFT_REJECTION+0.080
- APICAL_SURFACE+0.080
Top 10 suppressed
- TGF_BETA_SIGNALING-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- UV_RESPONSE_DN-0.440
- MITOTIC_SPINDLE-0.390
- WNT_BETA_CATENIN_SIGNALING-0.390
- APICAL_JUNCTION-0.350
- TNFA_SIGNALING_VIA_NFKB-0.350
- P53_PATHWAY-0.330
- APOPTOSIS-0.300
- PI3K_AKT_MTOR_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R11 | — | — | 0.822 |
| 2 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.821 |
| 3 | TCGA-E7-A4IJ-01A-31R-A26T-07 | — | — | 0.814 |
| 4 | TCGA-78-7147-01A-11R-2039-07 | — | cohortA1 | 0.812 |
| 5 | TCGA-IQ-A61I-01A-11R-A30B-07 | — | — | 0.802 |
| 6 | SRR4195696 | — | — | 0.777 |
| 7 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.773 |
| 8 | SRR33346946 | — | — | 0.773 |
| 9 | SRR25617833 | — | B | 0.761 |
| 10 | SRR23303738 | — | — | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.020 | Idelalisib | — uncovered |